Regeneron Pharmaceuticals Inc (NASDAQ:REGN) - Share price

Stock Report

Regeneron Pharmaceuticals Inc REGN

Balance Sheet Items (in % Terms)
Cash & Short Term Investments23.26%18.63%14.89%16.08%23.95%
Accounts receivable26.28%26.17%23.11%22.53%19.12%
Other Current Assets3.12%2.91%1.87%2.57%2.07%
Total current assets55.98%51.97%45.60%49.46%54.95%
Net PP&E25.16%28.42%29.88%26.91%21.95%
Other Long-Term Assets18.86%19.61%24.52%23.63%23.10%
Total Assets100.00%100.00%100.00%100.00%100.00%
Accounts Payable2.57%2.51%1.94%2.03%1.86%
Current Debt-----
Taxes Payable--3.38%0.00%0.18%
Accrued liabilities9.94%8.97%7.29%7.26%6.40%
Other current liabilities4.40%2.98%5.20%3.66%3.86%
Total current liabilities16.91%14.46%17.80%12.96%12.30%
Long Term Debt3.79%----
Other long-term liabilities13.64%----
Total Liabilities34.34%34.84%36.20%29.90%25.37%
Total stockholders' equity65.66%65.16%63.80%70.10%74.63%
Total Liabilities and Equity100.00%100.00%100.00%100.00%100.00%
Liquidity/Financial Health
Current Ratio3.313.592.563.824.47
Quick Ratio2.933.102.132.983.50
Financial Leverage1.521.531.571.431.34
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2019 Morningstar. All rights reserved.